TAMPA, Fla. — OncoBay Clinical, one of Moffitt Cancer Center’s for-profit subsidiaries, has partnered with Clinscience, a global clinical research organization based in Warsaw, Poland. The investment gives NEUCA Group, Clinscience’s parent company, a majority equity stake in OncoBay. Both companies will work together to advance immuno-oncology research for a global portfolio of clients.
Moffitt created OncoBay in 2019 as a boutique clinical research organization that offers streamlined, custom-curated services for biopharma and biotech companies conducting research in the immuno-oncology space. During this time, OncoBay has grown to providing services to more than 60 customers, with many trials conducted in tandem with Clinscience. This new partnership builds upon a two-year relationship with Clinscience.
“Moffitt made an investment three years ago when it launched OncoBay, and in that short period of time we have taken this concept to a global entity with an international research footprin” said James Mulé, IPhD, associate center director of Translational Science at Moffitt and OncoBay advisor. “This new partnership with Clinscience will allow us to continue to provide tailored immuno-oncology on a much larger scale.”
“This innovation collaboration gives us an exciting opportunity to build upon our clinical expertise, innovative analytics and data assessment tools to impact immuno-oncology research globally. The goal is to transform and accelerate discoveries to reach patients more quickly,” said Krystyna Kowalczyk, OncoBay CEO and co-founder.
Kowalczyk will remain CEO of the combined OncoBay and Clinscience operation. She and
Dannelle Palmer, OncoBay’s chief operating officer, will also join NEUCA Group’s leadership team.
Pillsbury Winthrop Shaw Pittman LLP served as legal adviser to NEUCA Group and Clinscience in the transaction. Ropes & Gray LLP served as legal adviser to OncoBay and Moffitt.
About Moffitt Cancer Center
Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
About OncoBay Clinical
OncoBay Clinical is a boutique CRO specializing in immuno-oncology/cell therapy, offering full-service custom curated CRO solutions for global pharmaceutical and biotech companies looking to advance their immuno-oncology product or device. As for-profit subsidiary of Moffitt Cancer Center, OncoBay embeds scientific expertise, operational excellence, and integrated cell manufacturing capabilities providing true end-to-end control. Built on years of IO and cell therapy expertise, a streamlined technology framework, a highly trained site network, and a dedicated team of experienced professionals, OncoBay is committed to operational excellence from start to finish. For more information, visit Oncobay.com and follow us on Facebook, Twitter, and LinkedIn.
Clinscience is a global company offering smart CRO services, from protocol development to final study report. It has offices in Poland, Spain, Italy, Germany, India, and the USA, and provides its services in 6 European countries. So far, over 150 biotechnology clients in Europe and around the world have trusted the Clinscience brand. Data-driven procedures and approach, combined with the Genius Suite™ technology, provide high flexibility and efficiency in meeting customer expectations. As part of the listed parent company NEUCA Group, specializing in wholesale pharmaceuticals and healthcare, Clinscience provides stability and organizational potential to meet the needs of commercial and non-commercial trials.
About Neuca Group
NEUCA Group has been operating in the healthcare sector for more than 30 years, combining the needs of pharmacists, manufacturers, and patients. It is a leader in the wholesale distribution of pharmaceuticals in Poland. The company looks after patient health by creating a network of 75 medical clinics. It is an expert in clinical research, managing 90+ Research Centers in Europe, First in Human facilities and integrated technology (eSource). Neuca is developing also ambitious telemedicine projects, and operates successfully in e-commerce and health insurance market. Since 2004, the NEUCA Group has been a publicly traded company listed on the Warsaw Stock Exchange, continually improving its financial results.